Fewer Experiments.Higher Hit Rates.
Orbion predicts how your protein will behave from sequence alone — expression yield, stability, and developability — so you rank a long list of candidates down to the few worth making, before you touch the bench.
Trusted by Biotech and Academic Labs
Protein Production Is a Guessing Game
You design a bunch of constructs, commit them to the bench, and wait weeks to learn which ones were never going to express. Every round of trial and error costs plates and months you don't get back — and the targets only get harder.
It Won't Express
A few residues can decide whether a construct even expresses — and you find that out weeks later, one plate at a time.
It Won't Stay Folded
Stabilising a membrane target means screening dozens of mutants for a couple of usable hits.
Structure Isn't the Answer
AlphaFold gives you a fold — not a construct, a yield, or a mutation that survives the bench.
One Workspace, from Sequence to Bench-Ready
Characterize a protein, rank stabilising mutations, score and pick constructs, and generate the protocol — every angle in one tool, including the one a structure model skips: which construct actually expresses.
Tumor Necrosis Factor
| Method | Host | Construct | Yield | Developability | |
|---|---|---|---|---|---|
| Reference | Cell Free | N Target C | 41.2 | 50.0 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C Target (80-227) C | 91.2 | 63.1 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C His8 Target (80-233) C | 86.5 | 68.9 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C Target (80-233) Strep-tag II C | 84.0 | 68.9 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C His8 Target (80-233) C | 82.7 | 68.9 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C His8 Target (80-227) C | 79.3 | 63.1 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C His6 Target (80-227) C | 73.5 | 63.1 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C His6 Target (80-233) His6 C | 61.8 | 68.9 | |
| Combinatorial | Cell Free | N SUMO MBP HRV 3C His8 Target (80-233) Strep-tag II C | 44.2 | 68.9 |
Everything You Need, from Sequence to Bench-Ready
Four engines on one platform — generate options, rank the right ones, and take only the winners to the lab.
Characterize
Everything you can know about a protein from its sequence, before you order a single primer.
Stabilize
Rank mutations by predicted stability gain — surface the stabilising variants worth testing.
Design
Rank constructs by predicted yield — the strong signal — with an early developability read (solubility, aggregation, PTM liabilities) to flag the risky ones before you clone.
Bench
Turn in-silico picks into a protocol — literature-grounded, adapted to your target and host.
From Thousands of Candidates to the Few Worth Making
Every construct and mutation, scored before a single one is built — so only the highest-ranked handful reaches the bench.
Validated at the Bench
Backed by Wet-Lab Results — Not Just Benchmarks
We test predictions prospectively and blind against real experiments, and we report the sample size and where the models are still weak. The signal is in the ranking — the absolute numbers still need your wet lab.
Ranked TNF-α Variants for Yield — Blind
An early blind pilot — 24 cell-free constructs ranked for yield before any were made. Promising, and honestly small.
Called GPCR Stability the Right Direction 78% of the Time
Signed ΔTm across 190 mutations in 7 GPCR receptors vs. experiment — our hardest target, and a directional pre-screen for stabilising mutations.
Predicted a Yield-Developability Trade-off — Confirmed at the Bench
Orbion kept the C-terminal residues most people trim — trading raw yield for a more developable molecule, ranked higher in advance.
Numbers on our proteins only prove so much. Every engagement starts with a prospective, blind benchmark on your own targets — so you see how it performs on the proteins you actually care about before you commit.
Benchmark Your TargetProtein Families
Built for the Hardest Targets
Orbion is strongest on membrane proteins and hard-to-express targets — the family where most tools give up. It extends to enzymes, antibodies, and binders; our validation is deepest where the targets are hardest.
Antibodies
mAbs & Fragments
Nanobodies
Single-Domain
Kinases
Signalling
Cytokines
Secreted
Built for Enterprise
Private. Secure. Yours.
Your sequences and results stay private and entirely yours — never used to train models for anyone else. You keep full ownership of your IP: no royalties, no milestone payments, just a subscription.
Explore Security & TrustInference-Only, Private
We run inference on your sequences — we don't train on your data, and nothing crosses between customers.
Full IP Ownership
No royalties, no milestones — every prediction and result is yours.
EU-Hosted
Your sequences and data are processed and stored in the EU, and deleted on request.
ISO 27001 In Progress
Our ISMS is being built to the ISO 27001 standard — certification in process, DPA available on request.
Questions Scientists Ask Us
From sequence alone: structure and per-residue confidence, PTMs, binding pockets, and membrane topology — and, on top of that, scores for expression yield and developability, plus ranked stabilizing mutations. The output is a shortlist of what to clone, express, and test.
Stop Guessing. Start Deciding.
Run your hardest target through Orbion and see how close the predictions land to your own lab data — before you commit a single experiment.
